Novira Therapeutics raised $2.5 million in a second round of seed financing Tuesday.
The Radnor, Pa., biopharmaceutical company is developing treatments for viral diseases including hepatitis B and HIV.
The financing was led by three Philadelphia angel groups: Delaware Crossing Investor Group Delaware Crossing Investor Group Latest from The Business Journals Kenexa CEO Karsan co-writes New York Times best sellerTicketLeap bounds ahead with fundsAngels bless enviro-friendly packager Follow this company , the Mid-Atlantic Angel Group Fund II and Robin Hood Ventures.
BioAdvance, Novira’s initial investor after the company was launched in 2009, also participated in the round.
Novira Therapeutics raised $2.5 million in a second round of seed financing Tuesday.
The Radnor, Pa., biopharmaceutical company is developing treatments for viral diseases including hepatitis B and HIV.
The financing was led by three Philadelphia angel groups: Delaware Crossing Investor Group Delaware Crossing Investor Group Latest from The Business Journals Kenexa CEO Karsan co-writes New York Times best sellerTicketLeap bounds ahead with fundsAngels bless enviro-friendly packager Follow this company , the Mid-Atlantic Angel Group Fund II and Robin Hood Ventures.
BioAdvance, Novira’s initial investor after the company was launched in 2009, also participated in the round.
RSS feed for comments on this post · TrackBack URI
Leave a reply